Brussels– 23 June 2015– As a major financing centre for biotechnology companies in Europe, EnterNext, the Euronext subsidiary designed to promote and grow the market for small and mid cap companies,expressed its support to EuropaBio on the occasion of the organisation of its event on the Benefits of Biotechnology at the European Parliament. For years, EuropaBio has been representing the interests of industrial, healthcare and agrifood biotechnology with the different European institutions. This landmark EuropaBio event aims at giving a snapshot of the significance and importance of biotech today in relation to the grand challenges we face in Europe.
To celebrate the opening of EuropaBio’s Event on the Benefits of Biotechnology, Carlo Incerti, EuropaBio Chair and Philippe De Backer, Member of the European Parliament, were invited to ring the bell to open the trading on the European market of Euronext. They were joined by Vincent Van Dessel, CEO of Euronext Brussels and Alain Baetens, Head of Listings of Euronext Brussels.
Alain Baetens, Head of Listings of Euronext Brussels, stated: “The EuropaBio event puts the European biotechnology sector at the forefront of the real economy, underscoring its great value for health and the creation of jobs in Europe. The biotechnology sector also creates investment opportunities for retail and institutional investors, and access to financing for innovative entrepreneurs. Our EnterNext platform holds a leading position in Europe in terms of IPOs for the biotechnology sector. Therefore, we strongly favour such federating initiatives, leveraged with the full support of the European institutions.”